Breaking News

Lonza Acquires PharmaCell

Offers core expertise in autologous cell and gene therapy manufacturing

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza has acquired PharmaCell B.V., a cell and gene contract manufacturer in Europe with employees in Maastricht and Geleen (NL). In 2016 PharmaCell had sales of €11 million. PharmaCell was primarily selected due to its core expertise in autologous cell and gene therapy manufacturing, which includes experience with two commercial advanced therapy medicinal products (ATMPs)-licensed products. Autologous therapies use a patient’s own cells. “PharmaCell’s position in the market compleme...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters